focus -WSS

focus

author：comprehensive 2025-10-02 23:30:33 - browse：49

Several amyloid plaques forming between neurons in a brain — Adobe

Expert advisers to the Food and Drug Administration on Friday voted unanimously in favor of expanding the approval of Leqembi, an Alzheimer’s disease treatment from Eisai and Biogen, further clearing the way for what could be the first widely available medicine that delays the disease’s progress.

The group voted 6-0 that an 1,800-patient study of Leqembi confirmed its benefits for patients in the early stages of Alzheimer’s, recommending the FDA widen the drug’s limited approval. The agency, which is not required to follow the suggestions of its advisers, is expected to make a final decision on Leqembi by July 6.

“I thought the clinical results were robust,” said Merit Cudkowicz, a neurologist from Massachusetts General Hospital and one of the experts invited to review Leqembi.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： The high cost of giving birth even with insurance
Next article： STAT Executive Editor Rick Berke on STAT's 8th birthday

WSS

FDA approves potent Eli Lilly obesity drug, Zepbound

Don't let 'shelved assets' gather dust. Make them into new lifesaving drugs

Medicare solvency divides Republicans at the presidential debate

Removing probiotics from the NICU could threaten preemies' health

Victims of gun violence feel impacts long after bullet wound

Extreme heat events are a public health emergency

hotspot

focus

explore

BioMarin wins approval for gene therapy to treat hemophilia A

The Sacklers, horror, and ‘The Fall of the House of Usher’

In age of alternative facts, a scholarly course on calling out crap

Study: New antibiotic targets gonorrhea as well as last existing drug

Virginia high school admissions case could be legal follow

Diversify hospital leadership teams to protect BIPOC patient health

23andMe had bad news about my health. I wish a person had delivered it

Vertex non

Medical records are filled with copy

FDA approves Recor Medical high blood pressure device

focus

More doctors should go into startup world

Biotech incubator Curie.Bio graduates its first startup

Removing probiotics from the NICU could threaten preemies' health

Biden administration opens offers in Medicare drug price negotiations

Juul spent big to court Black leaders to promote its e

Biotech incubator Curie.Bio graduates its first startup

leisure time

hotspot

hotspot

focus